Pharmalot, Pharmalittle: Merck may soon leapfrog rivals in immunotherapy race – STAT
TheStreet.com |
Pharmalot, Pharmalittle: Merck may soon leapfrog rivals in immunotherapy race
STAT The Food and Drug Administration granted priority review for combining Merck's Keytruda immunotherapy with chemotherapy as an initial treatment for advanced lung cancer. “This comes as an important surprise because if FDA approves the application, … Merck just leapt ahead of its rivals in the lung cancer drug race Merck Lung-Cancer Drug May Get OK For Large Patient Population Speedy review for Merck's Keytruda/chemo combo |
